Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 14 2025
0mins
Source: Barron's
- Hedge Fund Activity: A secretive hedge fund focused on biotechnology has purchased shares of Kymera Therapeutics.
- Stock Performance: This acquisition occurred after Kymera Therapeutics' stock reached its highest level on record.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 336.160
Low
385.00
Averages
403.76
High
424.00
Current: 336.160
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
Continue Reading
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
- Market Volatility: On Wednesday, the S&P 500 and Dow retreated from their highs, indicating a shift in market sentiment that could influence short-term investor decisions and risk appetite.
- Nasdaq Performance: Although the Nasdaq index pared gains, it still shows potential for growth, suggesting that volatility in tech stocks may provide short-term trading opportunities for investors.
- Buy Signals: Stocks of Eli Lilly and Google flashed buy signals, potentially attracting investor attention to the growth prospects of these companies in their respective sectors, which could drive their stock prices higher.
- Investor Strategy Adjustment: The market fluctuations and buy signals may prompt investors to reassess their portfolios, particularly in the current economic environment, seeking more promising investment opportunities.
Continue Reading